Cite
HARVARD Citation
Rittmeyer, A. et al. (n.d.). 123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression. Immuno-oncology technology. p. . [Online].